UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

The lancet oncology, 2019-06, Vol.20 (6), p.849-861

2019

Volltextzugriff (PDF)

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

Annals of oncology, 2018-01, Vol.29 (1), p.154-161

2018

Volltextzugriff (PDF)

A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study

Breast cancer research and treatment, 2019-02, Vol.174 (1), p.187-196

2019

Volltextzugriff (PDF)

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

Annals of oncology, 2012-03, Vol.23 (3), p.610-617

2012

Volltextzugriff (PDF)

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

Annals of oncology, 2013-09, Vol.24 (9), p.2382-2389

2013

Volltextzugriff (PDF)

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer

Annals of oncology, 2014-01, Vol.25 (1), p.132-138

2014

Volltextzugriff (PDF)

OHERA: A real world study of cardiac events in > 3700 patients with her2-positive early breast cancer treated with trastuzumab: Final analysis

ANNALS OF ONCOLOGY, 2017-09, Vol.28, p.v52-v52

2017

Volltextzugriff (PDF)

First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study

Annals of oncology, 2012-01, Vol.23 (1), p.111-118

2012

Volltextzugriff (PDF)

Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers

Bone marrow transplantation (Basingstoke), 2013-07, Vol.48 (7), p.915-921

2013

Volltextzugriff (PDF)

P14.03 Meninges metastases in breast cancer-one center study experience of concomitant therapy intrathecal and systemic

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii102-iii102

2017

Volltextzugriff (PDF)

2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)

European journal of cancer (1990), 2015-09, Vol.51, p.S532-S532

2015

Volltextzugriff (PDF)

P30.07 Can Response to Chemotherapy Be a Surrogate of Response to Immunotherapy in Second and Subsequent Lines- Real World Data

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S396-S397

2021

Volltextzugriff (PDF)

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

Journal of clinical oncology, 2015-05, Vol.33 (14), p.1564-1573

2015

Volltextzugriff (PDF)

Patients with classical Hodgkin lymphoma (CHL) and treatment failure despite a negative iPET have poor outcomes as patients with positive iPET and treatment escalation

Hematological oncology, 2017-06, Vol.35 (S2), p.313-315

2017

Volltextzugriff (PDF)

Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study

Annals of oncology, 2016-05, Vol.27 (5), p.834-842

2016

Volltextzugriff (PDF)

P3.01-17 Long Survivors with Advanced Lung Cancer - Efficacy and Tolerability of Nivolumab

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S873-S874

2018

Volltextzugriff (PDF)

VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study

Annals of oncology, 2022-02, Vol.33 (2), p.229-230

2022

Volltextzugriff (PDF)

Rosia: A Single-Arm Study in More Than 1000 Patients (PTS) Receiving Front-Line Bevacizumab (BEV) + Chemotherapy (CT) for Ovarian Cancer (OC)

Annals of oncology, 2012-09, Vol.23, p.ix322-ix323

2012

Volltextzugriff (PDF)

978P - Rosia: A Single-Arm Study in More Than 1000 Patients (PTS) Receiving Front-Line Bevacizumab (BEV) + Chemotherapy (CT) for Ovarian Cancer (OC)

Annals of oncology, 2012-09, Vol.23, p.ix322-ix323

2012

Volltextzugriff (PDF)

Randomised Phase II Study of Axitinib or Bevacizumab Combined with Paclitaxel/Carboplatin (PAC/CARB) as First-Line Therapy for Patients (PTS) with Advanced Non–Small Cell Lung Cancer (NSCLC)

Annals of oncology, 2012-09, Vol.23, p.ix408

2012

Volltextzugriff (PDF)

Phase I―II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

British journal of cancer, 2013, Vol.109 (6), p.1451-1459

2013

Volltextzugriff (PDF)

Patients with classical H odgkin lymphoma ( CHL ) and treatment failure despite a negative iPET have poor outcomes as patients with positive iPET and treatment escalation

Hematological oncology, 2017-06, Vol.35 (S2), p.313-315

2017

Volltextzugriff (PDF)

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(83)

Publikationsform

Artikel
(97)
Tagungsberichte
(1)

Sprache

Englisch
(86)
Polnisch
(11)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(51)
Life Sciences & Biomedicine
(45)
Female
(36)
Humans
(33)
Male
(29)
Adult
(26)
Neurosciences & Neurology
(26)
Endocrinology & Metabolism
(25)
Middle Aged
(25)
Neurosciences
(25)
Aged
(22)
Animals
(20)
Rats
(19)
Oncology
(12)
Rats, Inbred Wky
(11)
Aged, 80 And Over
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Cells, Cultured
(10)
Biological And Medical Sciences
(9)
Neoplasm Staging
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group Study

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer

OHERA: A real world study of cardiac events in > 3700 patients with her2-positive early breast cancer treated with trastuzumab: Final analysis

First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study

Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers

P14.03 Meninges metastases in breast cancer-one center study experience of concomitant therapy intrathecal and systemic

2702 Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)

P30.07 Can Response to Chemotherapy Be a Surrogate of Response to Immunotherapy in Second and Subsequent Lines- Real World Data

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

Patients with classical Hodgkin lymphoma (CHL) and treatment failure despite a negative iPET have poor outcomes as patients with positive iPET and treatment escalation

Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

P3.01-17 Long Survivors with Advanced Lung Cancer - Efficacy and Tolerability of Nivolumab

VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study

Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group

Rosia: A Single-Arm Study in More Than 1000 Patients (PTS) Receiving Front-Line Bevacizumab (BEV) + Chemotherapy (CT) for Ovarian Cancer (OC)

978P - Rosia: A Single-Arm Study in More Than 1000 Patients (PTS) Receiving Front-Line Bevacizumab (BEV) + Chemotherapy (CT) for Ovarian Cancer (OC)

Randomised Phase II Study of Axitinib or Bevacizumab Combined with Paclitaxel/Carboplatin (PAC/CARB) as First-Line Therapy for Patients (PTS) with Advanced Non–Small Cell Lung Cancer (NSCLC)

Phase I―II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

Patients with classical H odgkin lymphoma ( CHL ) and treatment failure despite a negative iPET have poor outcomes as patients with positive iPET and treatment escalation

Suchergebnisse filtern